

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6622697

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SANGKON OH	11/17/2016
SANDRA ZURAWSKI	11/17/2016
HYEMEE JOO	11/17/2016
GERARD ZURAWSKI	11/17/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BAYLOR RESEARCH INSTITUTE
<b>Street Address:</b>	2001 BRYAN ST, STE 2200
<b>City:</b>	DALLAS
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75201
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17301123
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	aoipdocket@nortonrosefulbright.com
<b>Correspondent Name:</b>	NORTON ROSE FULBRIGHT US LLP
<b>Address Line 1:</b>	98 SAN JACINTO BLVD, SUITE 1100
<b>Address Line 4:</b>	AUSTIN, TEXAS 78701
<b>ATTORNEY DOCKET NUMBER:</b>	BHCSP0416USC1/1001159912
<b>NAME OF SUBMITTER:</b>	MYRIAH J CLARK
<b>SIGNATURE:</b>	/Myriah J Clark/
<b>DATE SIGNED:</b>	03/25/2021
<b>Total Attachments: 2</b>	
source=bhcsp0416usc1_assignment#page1.tif	
source=bhcsp0416usc1_assignment#page2.tif	

ASSIGNMENT

WHEREAS, the undersigned (individually "ASSIGNOR" and collectively "ASSIGNORS"), are named inventors of the patent(s)/application(s) identified below (collectively "Patent(s)"),

AND WHEREAS Baylor Research Institute, having a place of business at 3310 Live Oak Street, Suite 501, Dallas, TX 75204 ("ASSIGNEE"), is desirous of acquiring all right, title and interest in and to the Patent(s);

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, each ASSIGNOR does hereby:

IRREVOCABLY SELLS, ASSIGNS, AND TRANSFERS to the ASSIGNEE ASSIGNOR's entire right, title, and interest throughout the world in U.S. Provisional Patent Application No. 61/994,239, filed May 16, 2014, and U.S. Provisional Patent Application No. 62/014,504, filed June 19, 2014, titled "METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE AND INFLAMMATORY CONDITIONS", including all information disclosed therein, such right, title, and interest including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement. For the avoidance of doubt, this sale, assignment, and transfer extends to all ASSIGNOR's right, title, and interest in all patents and applications (throughout the world) of any kind that claim priority to or otherwise issue from any of the Patent(s), including any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents and/or patent applications;









WARRANTS AND COVENANTS that ASSIGNOR has the authority to enter this ASSIGNMENT agreement, and that ASSIGNOR has done nothing and will not do anything to impair the rights conveyed to ASSIGNEE by this Agreement;

COVENANTS that, when requested and at the expense of the ASSIGNEE, ASSIGNOR will carry out in good faith the intent and purpose of this Agreement, including but not limited to executing any and all documents in connection with the Patent(s) and any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents, and/or patent applications claiming priority to, or based on any information disclosed in any of the Patent(s), including all rightful oaths, declarations, assignments, powers of attorney, and other papers; communicate to the ASSIGNEE all facts known to the ASSIGNOR relating to all information disclosed in the Patent(s) and the history thereof; and generally do everything possible that the ASSIGNEE shall consider desirable for vesting title to the Patent(s) and such patents and/or patent applications in the ASSIGNEE, and for securing, maintaining, and enforcing patent protection for the Patent(s) and such patents and/or patent applications;

WAIVES any right it has to challenge the adequacy of the consideration; and

AGREES that this Agreement is binding on ASSIGNOR's heirs, assigns, representatives, and successors.

**ASSIGNOR****ASSIGNEE**

	
Name: SangKon OH	Date
	
Name: Sandra ZURAWSKI	Date
	
Name: Hyemee JOO	Date
	
Name: Gerard ZURAWSKI	Date

Name: Jaime Walkowiak	Date
Title: COO/Baylor Research Institute	

ASSIGNMENT

WHEREAS, the undersigned (individually "ASSIGNOR" and collectively "ASSIGNORS"), are named inventors of the patent(s)/application(s) identified below (collectively "Patent(s)"),

AND WHEREAS Baylor Research Institute, having a place of business at 3310 Live Oak Street, Suite 501, Dallas, TX 75204 ("ASSIGNEE"), is desirous of acquiring all right, title and interest in and to the Patent(s);

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, each ASSIGNOR does hereby:

IRREVOCABLY SELLS, ASSIGNS, AND TRANSFERS to the ASSIGNEE ASSIGNOR's entire right, title, and interest throughout the world in U.S. Provisional Patent Application No. 61/994,239, filed May 16, 2014, and U.S. Provisional Patent Application No. 62/014,504, filed June 19, 2014, titled "METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE AND INFLAMMATORY CONDITIONS", including all information disclosed therein, such right, title, and interest including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement. For the avoidance of doubt, this sale, assignment, and transfer extends to all ASSIGNOR's right, title, and interest in all patents and applications (throughout the world) of any kind that claim priority to or otherwise issue from any of the Patent(s), including any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents and/or patent applications;

WARRANTS AND COVENANTS that ASSIGNOR has the authority to enter this ASSIGNMENT agreement, and that ASSIGNOR has done nothing and will not do anything to impair the rights conveyed to ASSIGNEE by this Agreement;

COVENANTS that, when requested and at the expense of the ASSIGNEE, ASSIGNOR will carry out in good faith the intent and purpose of this Agreement, including but not limited to executing any and all documents in connection with the Patent(s) and any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents, and/or patent applications claiming priority to, or based on any information disclosed in any of the Patent(s), including all rightful oaths, declarations, assignments, powers of attorney, and other papers; communicate to the ASSIGNEE all facts known to the ASSIGNOR relating to all information disclosed in the Patent(s) and the history thereof; and generally do everything possible that the ASSIGNEE shall consider desirable for vesting title to the Patent(s) and such patents and/or patent applications in the ASSIGNEE, and for securing, maintaining, and enforcing patent protection for the Patent(s) and such patents and/or patent applications;

WAIVES any right it has to challenge the adequacy of the consideration; and

AGREES that this Agreement is binding on ASSIGNOR's heirs, assigns, representatives, and successors.

**ASSIGNOR**


Name: SangKon OH \_\_\_\_\_ Date \_\_\_\_\_

Name: Sandra ZURAWSKI \_\_\_\_\_ Date \_\_\_\_\_

Name: Hyemee JOO \_\_\_\_\_ Date \_\_\_\_\_

Name: Gerard ZURAWSKI \_\_\_\_\_ Date \_\_\_\_\_

**ASSIGNEE**

 \_\_\_\_\_  
Name: Jaime Walkowiak \_\_\_\_\_ Date: 11/28/14  
Title: COO/Baylor Research Institute